[1] THAKKAR J P,DOLECEK T A,HORBINSKI C,et al. Epidemiologic and molecular prognostic review of glioblastoma[J]. Cancer Epidemiol Biomarkers Prev,2014, 23(10):1985-1996.
[2] YANG P, WANG Y, PENG X, et al. Management and survival rates in patients with glioma in China (2004-2010):a retrospective study from a single-institution[J]. J Neurooncol, 2013, 113(2):259-266.
[3] GILBERT M R, WANG M, ALDAPE K D, et al. Dose-dense temozolomide for newly diagnosed glioblastoma:a randomized phase Ⅲ clinical trial[J]. J Clin Oncol, 2013, 31(32):4085-4091.
[4] STUPP R, MASON W P, VAN DEN BENT M J, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10):987-996.
[5] 薛强. 恶性胶质瘤术后同期推量调强放疗的疗效及其预后影响因素分析[J]. 东南大学学报(医学版), 2016, 35(5):746-751.
[6] MARKOVIC D S, VINNAKOTA K, CHIRASANI S, et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion[J]. Proc Natl Acad Sci U S A, 2009, 106(30):12530-12535.
[7] 刘兆宇, 苏君, 金华, 等. 脑肿瘤微环境影响胶质母细胞瘤侵袭行为的研究进展[J]. 中国神经肿瘤杂志, 2013, 11(2):127-131.
[8] ARCURI C, FIORETTI B, BIANCHI R, et al. Microglia-glioma cross-talk:a two way approach to new strategies against glioma[J]. Front Biosci(Landmark Ed), 2017, 22:268-309.
[9] HANAHAN D, WEINBERG R A. Hallmarks of cancer:the next generation[J]. Cell, 2011, 144(5):646-674.
[10] GABRUSIEWICZ K, ELLERT-MIKLASZEWSKA A, LIPKO M, et al. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas[J]. PLoS One, 2011, 6(8):e23902.
[11] JOSEPH B, VENERO J L. Microglia:methods and protocols[M]. Totowa, NJ:Humana Press, 2013:3-8.
[12] WU F, LUO T, MEI Y, et al. Simvastatin alters M1/M2 polarization of murine BV2 microglia via Notch signaling[J]. J Neuroimmunol, 2018, 316:56-64.
[13] MURRAY P J, ALLEN J E, BISWAS S K, et al. Macrophage activation and polarization:nomenclature and experimental guidelines[J]. Immunity, 2014, 41(1):14-20.
[14] NIMMERJAHN A. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo[J]. Science, 2005, 308(5726):1314-1318.
[15] PATEL A R, RITZEL R, MCCULLOUGH L D, et al. Microglia and ischemic stroke:a double-edged sword[J]. Int J Physiol Pathophysiol Pharmacol, 2013, 5(2):73.
[16] SAAS P, KAMINSKI S, PERRUCHE S. Prospects of apoptotic cell-based therapies for transplantation and inflammatory diseases[J]. Immunotherapy, 2013, 5(10):1055-1073.
[17] NGAMBENJAWONG C, GUSTAFSON H H, PUN S H. Progress in tumor-associated macrophage(TAM)-targeted therapeutics[J]. Adv Drug Deliv Rev, 2017, 114:206-221.
[18] KOMOHARA Y, OHNISHI K, KURATSU J, et al. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas[J]. J Pathol, 2008, 216(1):15-24.
[19] ORIHUELA R, MCPHERSON C A, HARRY G J. Microglial M1/M2 polarization and metabolic states[J]. Br J Pharmacol, 2016, 173(4):649-665.
[20] SZULZEWSKY F, PELZ A, FENG X, et al. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1[J]. PLoS One, 2015, 10(2):e116644.
[21] WU A, WEI J, KONG L, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia[J]. Neuro Oncol, 2010, 12(11):1113-1125.
[22] GIERYNG A, PSZCZOLKOWSKA D, WALENTYNOWICZ K A, et al. Immune microenvironment of gliomas[J]. Lab Invest, 2017, 97(5):498-518.
[23] CONIGLIO S J, EUGENIN E, DOBRENIS K, et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling[J]. Mol Med, 2012, 18(1):519-527.
[24] LI X, YAO W, YUAN Y, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma[J]. Gut, 2016, 66(1):157-167.
[25] MORESCO E M Y, LAVINE D, BEUTLER B. Toll-like receptors[J]. Curr Biol, 2011, 21(13):R488-R493.
[26] SARRAZY V, VEDRENNE N, BILLET F, et al. TLR4 signal transduction pathways neutralize the effect of Fas signals on glioblastoma cell proliferation and migration[J]. Cancer Lett, 2011, 311(2):195-202.
[27] TEWARI R, CHOUDHURY S R, GHOSH S, et al. Involvement of TNFα-induced TLR4-NF-κB and TLR4-HIF-1α feed-forward loops in the regulation of inflammatory responses in glioma[J]. J Mol Med, 2012, 90(1):67-80.
[28] GUPTA P, GHOSH S, NAGARAJAN A, et al. β-defensin-3 negatively regulates TLR4-HMGB1 axis mediated HLA-G expression in IL-1β treated glioma cells[J]. Cell Signal, 2013, 25(3):682-689.
[29] MUKHERJEE S, KARMAKAR S, BABU S P S. TLR2 and TLR4 mediated host immune responses in major infectious diseases:a review[J]. Braz J Infect Dis, 2016, 20(2):193-204.
[30] KAWAI T, AKIRA S. Toll-like Receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5):637-650.
[31] CHEN G, YUE Y, QIN J, et al. Plumbagin suppresses the migration and invasion of glioma cells via downregulation of MMP-2/9 expression and inaction of PI3K/Akt signaling pathway in vitro[J]. J Pharma Sci, 2017, 134(1):59-67.
[32] BELKAID A, FORTIER S, CAO J, et al. Necrosis Induction in glioblastoma cells reveals a new "bioswitch" function for the MT1-MMP/G6PT signaling axis in proMMP-2 activation versus cell death decision[J]. Neoplasia, 2007, 9(4):332-340.
[33] ZHENG H, TAKAHASHI H, MURAI Y, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma[J]. Anticancer Res, 2006, 26(5A):3579.
[34] CHEN D, PING Y, YU S, et al. Downregulating FPR restrains xenograft tumors by impairing the angiogenic potential and invasive capability of malignant glioma cells[J]. Biochem Biophys Res Commun, 2009, 381(3):448-452.
[35] KIM E S, KIM M S, MOON A. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells[J].Int J Oncol, 2004, 25(5):1375-1382.
[36] YE X, XU S, XIN Y, et al. Tumor-associated microglia/macrophages fnhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway[J]. J Immunol, 2012, 189(1):444.
[37] MANTOVANI A, SCHIOPPA T, PORTA C, et al. Role of tumor-associated macrophages in tumor progression and invasion[J]. Cancer Metastasis Rev, 2006, 25(3):315-322.
[38] HULPER P, SCHULZ-SCHAEFFER W, DULLIN C, et al. Tumor localization of an anti-TGF-beta antibody and its effects on gliomas[J]. Int J Oncol, 2011, 38(1):51-59.
[39] WESOLOWSKA A, KWIATKOWSKA A, SLOMNICKI L, et al. Microglia-derived TGF-β as an important regulator of glioblastoma invasion-an inhibition of TGF-β-dependent effects by shRNA against human TGF-β type Ⅱ receptor[J]. Oncogene, 2008, 27(7):918-930.
[40] ZHU C, KROS J M, CHENG C, et al. The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies[J]. Neuro Oncol, 2017, 19(11):1435-1446.
[41] BRANDENBURG S, MVLLER A, TURKOWSKI K, et al. Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors[J]. Acta Neuropathol, 2016, 131(3):365-378.
[42] NIJAGUNA M B, SCHRÖDER C, PATIL V, et al. Definition of a serum marker panel for glioblastoma discrimination and identification of Interleukin 1β in the microglial secretome as a novel mediator of endothelial cell survival induced by C-reactive protein[J]. J Proteomics, 2015, 128:251-261.
[43] ALITALO A K, PROULX S T, KARAMAN S, et al. VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis[J]. Cancer Res, 2013, 73(14):4212.
[44] VAN BEIJNUM J R, NOWAK-SLIWINSKA P, HUIJBERS E J M, et al. The great escape; the hallmarks of resistance to antiangiogenic therapy[J]. Pharmacol Rev, 2015, 67(2):441-461.
[45] PIAO Y, LIANG J, HOLMES L, et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype[J].Neuro Oncol, 2012, 14(11):1379-1392. |
